HUTCHMED (China) Ltd (NAS:HCM)
$ 21.75 0.93 (4.47%) Market Cap: 3.76 Bil Enterprise Value: 2.96 Bil PE Ratio: 40.46 PB Ratio: 5.21 GF Score: 85/100

HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call Transcript

May 02, 2022 / 12:00PM GMT
Release Date Price: $12.23 (-18.95%)
Operator

Good evening, good afternoon, and good morning. Welcome to the HUTCHMED conference call. (Operator Instructions) Please be advised that this call will be recorded. I will turn the call over to our first speaker today, Mark Lee, Senior Vice President of Corporate Finance and Development. Please go ahead.

Kin Hung Lee;China;Limited;SVP of Corporate Finance;Development
HUTCHMED

()-&

Thanks, Regina. Thank you, everybody, for attending the HUTCHMED conference call today to discuss the FDA update on surufatinib's NDA in neuroendocrine tumors. As most of you know, we issued a press release 2 hours ago detailing this current status, and it's on our website.

This call -- a replay of this call will be available after this concludes. So today, we have on the call our executive management team, Dr. Weiguo Su, Chief Executive Officer and Chief Scientific Officer; Dr. Marek Kania, Managing Director and Chief Medical Officer of HUTCHMED International; Johnny Cheng, our Chief Financial Officer; and Dr

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot